Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Amyloidosis × 30 days × Clear all

Phase

Phase 2 1 Phase 1/2 1 Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 95 Carcinoma, Non-Small-Cell Lung 83 Prostatic Neoplasms 75 Multiple Myeloma 58 Leukemia, Myeloid, Acute 54 Neoplasms 50 Colorectal Neoplasms 45 Lung Neoplasms 43 Squamous Cell Carcinoma of Head and Neck 35 Neoplasm Metastasis 35 Ovarian Neoplasms 34 Lymphoma 33 Melanoma 32 Brain Neoplasms 32 Triple Negative Breast Neoplasms 30 Pancreatic Neoplasms 29 Recurrence 27 Carcinoma, Renal Cell 27 Carcinoma, Hepatocellular 27 Urinary Bladder Neoplasms 24 Sarcoma 22 Lymphoma, Follicular 22 Leukemia, Lymphocytic, Chronic, B-Cell 22 Glioblastoma 22 Stomach Neoplasms 21 Lymphoma, Large B-Cell, Diffuse 20 Glioma 19 Uterine Cervical Neoplasms 18 Precursor Cell Lymphoblastic Leukemia-Lymphoma 18 Lymphoma, Non-Hodgkin 18

Interventions

belantamab mafodotin 1 Dexamethasone 1 Cyclophosphamide 1 Bortezomib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07224672 2026-03-17

ALANIS

GlaxoSmithKline

Phase 2 Not yet recruiting

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡